Notopterol Ameliorates Hyperuricemia-Induced Cardiac Dysfunction in Mice.

Area of Science:

• Pharmacology
• Cardiovascular Biology
• Molecular Medicine

Background:

• Hyperuricemia causes chronic inflammation and cardiac damage.
• The cardioprotective effects of notopterol in hyperuricemia are unknown.
• P2X7R and pyroptosis are implicated in hyperuricemia-related inflammation.

Purpose of the Study:

• To investigate the cardioprotective potential of notopterol in a hyperuricemia mouse model.
• To elucidate the underlying molecular mechanisms involving P2X7R and pyroptosis.

Main Methods:

• Hyperuricemia induced in mice using potassium oxonate and adenine.
• Treatment with notopterol (20 mg/kg) or allopurinol (10 mg/kg).
• Assessment of cardiac function, exercise capacity, and molecular markers (P2X7R, pyroptosis proteins) in vivo and in vitro (H9c2 cells).

Main Results:

• Hyperuricemia impaired cardiac function and exercise capacity.
• Notopterol treatment improved exercise capacity and alleviated cardiac dysfunction.
• Notopterol suppressed P2X7R and pyroptosis signaling pathways in vivo and in vitro.
• Inhibition of P2X7R by notopterol was crucial for its anti-pyroptosis effect.

Conclusions:

• Notopterol demonstrates cardioprotective effects in hyperuricemia by inhibiting the P2X7R/NLRP3 signaling pathway.
• Notopterol mitigates uric acid-induced pyroptosis and inflammation.
• Notopterol is a potential therapeutic candidate for managing hyperuricemia-associated cardiac dysfunction.